JSC Pharmstandard (PHST)

Executive Summary

JSC Pharmstandard is Russia's leading pharmaceutical group, focused on the development and manufacture of affordable generic medicines. With a portfolio of over 400 products across 30 dosage forms and state-of-the-art GMP-certified plants, the company holds a strong domestic market position. However, operations face headwinds from ongoing geopolitical tensions, sanctions, and currency volatility, which may impact supply chains and export potential. Despite these challenges, Pharmstandard's broad product range and essential medicine status provide revenue resilience. The company is also investing in new product development to capture growing demand in areas like oncology and cardiovascular diseases.

Upcoming Catalysts (preview)

• Q4 2026Launch of high-value generic drugs in oncology and cardiology65% success
• Q2 2026Inclusion in expanded state drug reimbursement programs70% success
• Q3 2026Strategic partnership for export to CIS and Middle East markets55% success